#USA #New York #Baird Medical #Medical Innovation #MWA Technology

Baird Medical's Remarkable Year in 2024

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), known for its pioneering work in minimally invasive Microwave Ablation (MWA) technology, is celebrating a landmark year characterized by groundbreaking innovations and various prestigious recognitions. As market conditions fluctuated globally, Baird Medical sustained its position at the vanguard of the medical technology field.

A Historic Nasdaq Listing

On October 2, 2024, Baird Medical achieved a critical milestone by successfully listing on the Nasdaq Stock Market. This strategic move underscores its commitment to expansion and innovation within the international market, focusing on bolstering shareholder value while leading advancements in MWA solutions.

Strengthening Intellectual Property

In line with its innovative mission, Baird Medical secured several new patents that will enhance MWA technology and improve production protocols. The patents include:

• - Invention Patent for a Semi-rigid Penetrating Microwave Ablation Antenna and Transmission Line Structure.
• - Invention Patent for an Assembly Method and Transmission Line Structure for a Semi-flexible Microwave Ablation Antenna.
• - Utility Model Patent for an Automated Drying Device.

These developments highlight Baird Medical's leadership in refining microwave ablation solutions, aiming to enhance patient care and operational efficiency.

Class III Medical Device Production License

Among its significant accomplishments, Baird Medical was granted a Class III Medical Device Production License in China. This pivotal license allows for increased production capabilities and broader access to the market for its advanced medical devices, further attesting to its enhanced credibility and operational capacity in the industry.

Industry Recognition and Awards

Baird Medical's unyielding dedication to research and development has gained accolades, affirming its influence in oncology treatments and medical advancements. Key recognitions include:

• - Establishment of the Suzhou Engineering Technology Research Center dedicated to Tumor Microwave Ablation treatments.
• - Jiangsu Province High-Tech Enterprise designation.
• - The Most Investment Value Award from the 10th China Medical Industry Innovation Competition.

Additionally, its subsidiary, Nanjing Great Wall, has distinguished itself by receiving patents focused on vascular thermal coagulation and innovative RF ablation catheters, reinforcing its standing in minimally invasive treatment technologies.

New Patents and Safety Verification

Nanjing Great Wall announced new patents, among which are:

• - Invention Patents for both a Semi-rigid Endovascular Microwave Thermal Coagulation Antenna and an Adjustable-Bending Radiofrequency Ablation Catheter.
• - Utility Model Patents for a Microwave Ablation Needle with Drilling Functions and a Microwave Ablation Probe.

Nanjing Great Wall also received the Class III Medical Device Registration Certificate (No. 20243010517) in China for its Disposable Microwave Ablation Needle, further proving its safety and clinical effectiveness. To improve its global market reach, it obtained ISO 13485 certification, indicating high-quality management practices in manufacturing medical devices.

Looking Ahead

With its accomplishments in 2024, Baird Medical is well-positioned to accelerate its global expansion initiatives, continue to innovate within the realm of next-generation ablation technologies, and solidify partnerships with leading healthcare institutions. The company remains committed to its mission of enhancing patient outcomes worldwide through the advancement of minimally invasive medical procedures.

For more information about Baird Medical and its groundbreaking work, please visit Baird Medical.